Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AML and High Risk MDS”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00480987
What this trial is testing

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid LeukemiaLeukemia
M.D. Anderson Cancer Center 27
Testing effectiveness (Phase 2)Study completedNCT00673114
What this trial is testing

Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

Who this might be right for
Hematologic MalignancyMyelodysplastic Syndrome (MDS)Aplastic Anemia
Joanne Kurtzberg, MD 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT02935361
What this trial is testing

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
University of Southern California 33
Testing effectiveness (Phase 2)UnknownNCT05823714
What this trial is testing

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

Who this might be right for
Allogeneic Hematopoietic Stem Cell TransplantationAcute Myeloid LeukemiaMyelodysplastic Syndrome
The First Affiliated Hospital of Soochow University 70
Testing effectiveness (Phase 2)Study completedNCT01707004
What this trial is testing

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities+9 more
University of Wisconsin, Madison 20
Testing effectiveness (Phase 2)Looking for participantsNCT03383575
What this trial is testing

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 63
Large-scale testing (Phase 3)Study completedNCT00469729
What this trial is testing

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Who this might be right for
Hematologic MalignanciesAcute Myeloid LeukemiaLymphoid Leukemia+4 more
Gamida Cell -Teva Joint Venture Ltd. 101
Early research (Phase 1)Ended earlyNCT02641002
What this trial is testing

CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Celgene 28
Testing effectiveness (Phase 2)Study completedNCT02221310
What this trial is testing

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
New York Medical College 25
Testing effectiveness (Phase 2)Study completedNCT01272245
What this trial is testing

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 36
Very early researchUnknownNCT04156256
What this trial is testing

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Testing effectiveness (Phase 2)UnknownNCT00328237
What this trial is testing

Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid Leukemia+2 more
Colorado Blood Cancer Institute 20
Testing effectiveness (Phase 2)Study completedNCT01729845
What this trial is testing

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Who this might be right for
Previously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid Leukemia
Fred Hutchinson Cancer Center 52
Large-scale testing (Phase 3)Study completedNCT03268954
What this trial is testing

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Takeda 454
Testing effectiveness (Phase 2)Study completedNCT03824080
What this trial is testing

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Who this might be right for
Acute Myeloid LeukemiaHigh-risk Myelodysplastic SyndromeLow-risk Myelodysplastic Syndrome
GWT-TUD GmbH 45
Testing effectiveness (Phase 2)Study completedNCT03047993
What this trial is testing

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White Cells+4 more
M.D. Anderson Cancer Center 28
Testing effectiveness (Phase 2)Looking for participantsNCT03128034
What this trial is testing

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia+9 more
Fred Hutchinson Cancer Center 75
Testing effectiveness (Phase 2)UnknownNCT02205164
What this trial is testing

Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients

Who this might be right for
Chemotherapy Induced Nausea and Vomiting
Associazione Salentina Angela Serra 134
Early research (Phase 1)Active Not RecruitingNCT02530034
What this trial is testing

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic and Lymphoid Cell Neoplasm+8 more
M.D. Anderson Cancer Center 72
Early research (Phase 1)Study completedNCT00807677
What this trial is testing

Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia+9 more
Millennium Pharmaceuticals, Inc. 31
Next Page